Clinical Outcomes in Hereditary Cancer
N/A
N/A
Both
Breast Cancer, Pancreatic Cancer
Trial Information
Clinical Outcomes in Hereditary Cancer
Compare the clinical characteristics and post-surgical outcomes (overall survival)of
pancreatic cancer patients of Ashkenazi descent with or without germline founder mutations
in BRCA1 or BRCA2 .
Compare the clinical characteristics and outcomes (time to progression) of breast cancer
patients of Ashkenazi descent with or without germline founder mutations in BRCA1 or BRCA2
receiving paclitaxel chemotherapy for metastatic disease.
Inclusion Criteria:
- Included in DB0363-03
- Jewish religious preference at registration
- Archival material available for testing
- Adequate post-surgical follow-up
- Jewish religious preference at registration
- Archival material available for testing
- Adequate follow-up to determine time to progression
Exclusion Criteria:
-Subjects will not be included in the analyses if a DNA sample cannot be obtained.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Retrospective
Outcome Measure:
The overall objective of the protocol is to examine the hypothesis that hereditary cancers are distinct in clinical characteristics and outcome from those that arise in the absence of a known predisposition.
Outcome Time Frame:
2 years
Safety Issue:
Yes
Principal Investigator
Mark Robson, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Memorial Sloan-Kettering Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
06-004
NCT ID:
NCT00580021
Start Date:
January 2006
Completion Date:
January 2014
Related Keywords:
- Breast Cancer
- Pancreatic Cancer
- Ashkenazi ancestry
- mutations in BRCA1 or BRCA2
- Breast Cancer
- Pancreatic Cancer
- Breast Neoplasms
- Pancreatic Neoplasms
Name | Location |
|---|---|
| Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |
